Abbott Laboratories [ABT] vs Dexcom [DXCM] Detailed Stock Comparison
Abbott Laboratories
NYSE
Loading...
Dexcom
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Abbott Laboratories wins in 18 metrics, Dexcom wins in 1 metrics, with 0 ties. Abbott Laboratories appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Abbott Laboratories | Dexcom | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 16.75 | 47.39 | Abbott Laboratories |
| Price-to-Book Ratio | 4.59 | 10.18 | Abbott Laboratories |
| Debt-to-Equity Ratio | 26.50 | 100.24 | Abbott Laboratories |
| PEG Ratio | 0.46 | 1.71 | Abbott Laboratories |
| EV/EBITDA | 20.85 | 27.85 | Abbott Laboratories |
| Profit Margin (TTM) | 32.43% | 13.29% | Abbott Laboratories |
| Operating Margin (TTM) | 19.73% | 18.37% | Abbott Laboratories |
| EBITDA Margin (TTM) | 19.73% | 18.37% | Abbott Laboratories |
| Return on Equity | 30.93% | 22.83% | Abbott Laboratories |
| Return on Assets (TTM) | 6.62% | 6.08% | Abbott Laboratories |
| Free Cash Flow (TTM) | $6.35B | $630.70M | Abbott Laboratories |
| Dividend Yield | 1.28% | N/A | N/A |
| 1-Year Return | 18.07% | -2.45% | Abbott Laboratories |
| Price-to-Sales Ratio (TTM) | 5.39 | 6.15 | Abbott Laboratories |
| Enterprise Value | $238.75B | $25.71B | Abbott Laboratories |
| EV/Revenue Ratio | 5.54 | 5.98 | Abbott Laboratories |
| Gross Profit Margin (TTM) | 56.44% | 59.53% | Dexcom |
| Revenue per Share (TTM) | $25 | $11 | Abbott Laboratories |
| Earnings per Share (Diluted) | $7.97 | $1.41 | Abbott Laboratories |
| Beta (Stock Volatility) | 0.70 | 1.49 | Abbott Laboratories |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Abbott Laboratories vs Dexcom Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Abbott Laboratories | -0.36% | -0.24% | 1.16% | -0.84% | 0.80% | 17.23% |
| Dexcom | 0.54% | -2.72% | -10.58% | -20.51% | -2.49% | -15.36% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Abbott Laboratories | 18.07% | 30.65% | 21.29% | 217.47% | 424.82% | 549.05% |
| Dexcom | -2.45% | -34.95% | -31.15% | 242.65% | 1,848.39% | 2,085.53% |
News Based Sentiment: Abbott Laboratories vs Dexcom
Abbott Laboratories
News based Sentiment: POSITIVE
Abbott Laboratories reported strong Q2 2025 earnings and raised its full-year guidance, leading to positive analyst upgrades and increased institutional investment. While the ongoing NEC litigation presents a risk, the overall narrative is positive, suggesting continued growth and profitability for the company.
Dexcom
News based Sentiment: MIXED
Dexcom experienced a month of conflicting signals. While Q2 earnings beat expectations and revenue grew, concerns about regulatory delays, product safety allegations, and analyst downgrades created significant volatility and uncertainty, making it a mixed bag for investors.
Performance & Financial Health Analysis: Abbott Laboratories vs Dexcom
| Metric | ABT | DXCM |
|---|---|---|
| Market Information | ||
| Market Cap | $231.60B | $26.16B |
| Market Cap Category | Mega cap | Large cap |
| 10 Day Avg. Volume | 6,299,450 | 8,183,612 |
| 90 Day Avg. Volume | 5,376,593 | 5,586,657 |
| Last Close | $132.99 | $66.44 |
| 52 Week Range | $110.86 - $141.23 | $57.52 - $93.25 |
| % from 52W High | -5.83% | -28.75% |
| All-Time High | $142.60 (Dec 27, 2021) | $164.86 (Nov 15, 2021) |
| % from All-Time High | -6.74% | -59.70% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.07% | 0.15% |
| Quarterly Earnings Growth | 0.37% | 0.25% |
| Financial Health | ||
| Profit Margin (TTM) | 0.32% | 0.13% |
| Operating Margin (TTM) | 0.20% | 0.18% |
| Return on Equity (TTM) | 0.31% | 0.23% |
| Debt to Equity (MRQ) | 26.50 | 100.24 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $29.05 | $6.56 |
| Cash per Share (MRQ) | $4.18 | $7.47 |
| Operating Cash Flow (TTM) | $9.04B | $987.70M |
| Levered Free Cash Flow (TTM) | $5.92B | $425.12M |
| Dividends | ||
| Last 12-Month Dividend Yield | 1.28% | N/A |
| Last 12-Month Dividend | $1.69 | N/A |
Valuation & Enterprise Metrics Analysis: Abbott Laboratories vs Dexcom
| Metric | ABT | DXCM |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 16.75 | 47.39 |
| Forward P/E | 25.87 | 32.91 |
| PEG Ratio | 0.46 | 1.71 |
| Price to Sales (TTM) | 5.39 | 6.15 |
| Price to Book (MRQ) | 4.59 | 10.18 |
| Market Capitalization | ||
| Market Capitalization | $231.60B | $26.16B |
| Enterprise Value | $238.75B | $25.71B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 5.54 | 5.98 |
| Enterprise to EBITDA | 20.85 | 27.85 |
| Risk & Other Metrics | ||
| Beta | 0.70 | 1.49 |
| Book Value per Share (MRQ) | $29.05 | $6.56 |
Financial Statements Comparison: Abbott Laboratories vs Dexcom
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | ABT | DXCM |
|---|---|---|
| Revenue/Sales | $10.36B | $1.04B |
| Cost of Goods Sold | $4.47B | $447.00M |
| Gross Profit | $5.89B | $589.00M |
| Research & Development | $716.00M | $145.20M |
| Operating Income (EBIT) | $1.69B | $133.70M |
| EBITDA | $2.66B | $219.00M |
| Pre-Tax Income | $1.78B | $154.30M |
| Income Tax | $453.00M | $48.90M |
| Net Income (Profit) | $1.33B | $105.40M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | ABT | DXCM |
|---|---|---|
| Cash & Equivalents | $6.53B | $904.90M |
| Total Current Assets | $23.15B | $4.55B |
| Total Current Liabilities | $13.00B | $3.04B |
| Long-Term Debt | $12.74B | $1.36B |
| Total Shareholders Equity | $49.06B | $2.27B |
| Retained Earnings | $47.72B | $1.70B |
| Property, Plant & Equipment | N/A | $59.10M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | ABT | DXCM |
|---|---|---|
| Operating Cash Flow | $1.42B | $167.90M |
| Capital Expenditures | $-484.00M | $-87.00M |
| Free Cash Flow | $933.00M | $96.80M |
| Debt Repayment | $-1.00B | N/A |
| Common Stock Repurchase | $-280.00M | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | ABT | DXCM |
|---|---|---|
| Shares Short | 18.07M | 13.14M |
| Short Ratio | 3.68 | 3.18 |
| Short % of Float | 0.01% | 0.04% |
| Average Daily Volume (10 Day) | 6,299,450 | 8,183,612 |
| Average Daily Volume (90 Day) | 5,376,593 | 5,586,657 |
| Shares Outstanding | 1.73B | 390.70M |
| Float Shares | 1.73B | 389.52M |
| % Held by Insiders | 0.01% | 0.00% |
| % Held by Institutions | 0.81% | 0.97% |
Dividend Analysis & Yield Comparison: Abbott Laboratories vs Dexcom
| Metric | ABT | DXCM |
|---|---|---|
| Last 12-Month Dividend | $1.69 | N/A |
| Last 12-Month Dividend Yield | 1.28% | N/A |
| 3-Year Avg Annual Dividend | $1.92 | N/A |
| 3-Year Avg Dividend Yield | 0.49% | N/A |
| 3-Year Total Dividends | $5.77 | N/A |
| Ex-Dividend Date | Jan 15, 2025 | N/A |